logo/base Created with Sketch.
logo echosens
en-us
chevron Contact
English US version chevron
Change region

International Clinical Practice Guidelines
Related to FibroScan®

These latest guidelines – for healthcare professionals only – define the role of diagnostic and treatment modalities in the management of patients with chronic liver disease. 

wave

The following recommendations are defined by internationally recognized scientific organizations and are based on the best available research data and practical experience. 

Recommendations in Hepatology & Gastroenterology

WHO Guidelines for the prevention, diagnosis, care and treatment
for people with chronic hepatitis B (CHB) infection chevron

In the new WHO guideline 2024 on the management of people with chronic hepatitis B infection, FibroScan® is specifically recommended as the transient elastography technique for initial assessment and treatment eligibility.

All adults and adolescents (aged ≥12 years) with chronic hepatitis B including pregnant women and girls and women of reproductive age will be eligible for treatment, if they show evidence of significant fibrosis (TE by FibroScan >7 kPa) or cirrhosis (TE by FibroScan >12.5 kPa).

These TE cut-off values (>7 kPa & >12.5 kPa) mentioned at the new WHO guideline 2024 on management of people with CHB infection applied to FibroScan® only.

> More information

NICE Guidance on FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist care chevron

The National Institute for Health and Care Excellence (NICE) in the United Kingdom has issued landmark guidance recommending the use of FibroScan®, citing that it may improve the early detection of liver disease in primary and community care settings.

> Access the NICE full publication

AASLD Practice Guidance on the Clinical Assessment and Management of Nonalcoholic Fatty Liver Disease chevron

The new Practice Guidance from the AASLD suggests the use of VCTE™, a patented technology used by FibroScan® solutions from Echosens, for detecting and diagnosing NAFLD in high-risk individuals, including those with type 2 diabetes (T2D).

> Access the publication

AGA Clinical Care Pathway for the Risk Stratification and Management of Patients With Nonalcoholic Fatty Liver Disease chevron

These AGA guidelines indicate how to determine which risk-factor patients will benefit from testing, the NIT-based FIB-4 + LSM by VCTE™ test sequence and risk-stratified disease management guidance.

> Access the AGA full publication

Baveno VII Renewing Consensus in Portal Hypertension chevron

These Baveno VII guidelines applies for the management of patients with advanced chronic liver disease.

> Access the publication

EASL Clinical Practice Guidelines on Non-invasive Tests for Evaluation of Liver Disease Severity and Prognosis chevron

These EASL guidelines are a big step towards non-invasive management of patients with liver disease.

> Access the publication

Recommendations in Diabetology & Endocrinology

AACE Clinical Practice Guidelines for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings chevron

These new guidelines are a breakthrough in early diagnosis and management of patients with NAFLD targeting primary care and endocrinology clinical settings.

> Access the publication

Recommendations in Cardiology

AHA Nonalcoholic Fatty Liver Disease and Cardiovascular Risk A Scientific Statement from the American Heart Association chevron

The purpose of this scientific statement is to review the underlying risk factors and pathophysiology of NAFLD, the associations with atherosclerotic cardiovascular disease, diagnostic and screening strategies, and potential interventions.

> Access the AHA full publication 

chevron Visit our clinical library
chevron Contact us